2024
Mechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightPeak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M. Peak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Kidney International Reports 2024, 9: 3035-3044. PMID: 39430198, PMCID: PMC11489825, DOI: 10.1016/j.ekir.2024.07.009.Peer-Reviewed Original ResearchLeft ventricular ejection fractionPulmonary artery pressureCreatinine doublingEGFR declineEjection fractionKidney outcomesHeart failurePeak tricuspid regurgitant jet velocityDoubling of serum creatinineTricuspid regurgitant jet velocityElevated pulmonary artery pressureAssociated with lower eGFRWorsening kidney functionVentricular ejection fractionRegurgitant jet velocityCox proportional hazards modelsProportional hazards modelPost hoc analysisBaseline eGFRSerum creatinineLow eGFRTOPCAT trialFollow-upKidney functionArterial pressureCOVID-19−Associated Acute Kidney Injury and Longitudinal Kidney Outcomes
Aklilu A, Kumar S, Nugent J, Yamamoto Y, Coronel-Moreno C, Kadhim B, Faulkner S, O’Connor K, Yasmin F, Greenberg J, Moledina D, Testani J, Wilson F. COVID-19−Associated Acute Kidney Injury and Longitudinal Kidney Outcomes. JAMA Internal Medicine 2024, 184: 414-423. PMID: 38407862, PMCID: PMC10897825, DOI: 10.1001/jamainternmed.2023.8225.Peer-Reviewed Original ResearchCOVID-19-associated acute kidney injuryCOVID-19-associated AKIAcute kidney injuryMulticenter cohort studyKidney function declineKidney functionKidney injuryCohort studyKidney outcomes of patientsIncidence of acute kidney injuryLong-term kidney outcomesHistorical cohort of patientsMultivariate time-to-event analysesPositive influenza ALongitudinal multicenter cohort studyWorsening kidney functionOutcomes of patientsAdverse kidney eventsCohort of patientsComposite of mortalityMarkers of illness severityAdult hospitalized patientsBaseline comorbidity scoreTime-to-event analysisFunctional declineSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original ResearchConceptsDiuretic resistanceCardiorenal syndromeHeart failureLoop diureticsDiuretic withdrawalHigh-dose loop diureticsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideGrowth differentiation factor 15Carbohydrate antigen 125Differentiation factor 15Sodium removalRandomized controlled studyCardiorenal parametersDiuretic doseSoluble ST2Natriuretic peptideMedian timeDiuretic responseKidney injuryPeritoneal membraneElectrolyte handlingKidney functionDiureticsInterleukin-6
2023
Association of Tricuspid Regurgitant Jet Velocity with Kidney Function in Patients with Heart Failure with Preserved Ejection Fraction in TOPCAT
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M. Association of Tricuspid Regurgitant Jet Velocity with Kidney Function in Patients with Heart Failure with Preserved Ejection Fraction in TOPCAT. Journal Of The American Society Of Nephrology 2023, 34: 144-144. DOI: 10.1681/asn.20233411s1144c.Peer-Reviewed Original Research
2021
Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ. Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. American Journal Of Kidney Diseases 2021, 80: 65-78. PMID: 34843844, PMCID: PMC9135960, DOI: 10.1053/j.ajkd.2021.09.026.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAcute heart failureEGFR declineHeart failureVolume overloadKidney functionNatriuretic peptideLower riskN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHeart Failure Outcome StudyLong-term kidney functionG4-G5Adverse kidney outcomesClinical congestion scoreKidney function declineGlomerular filtration rateCause-specific hazards modelKidney outcomesTolvaptan (EVEREST) trialCardiovascular outcomesVasopressin AntagonismImproved survivalFunction declineDecreased riskRenal negative pressure treatment as a novel therapy for heart failure-induced renal dysfunction
Rao VS, Maulion C, Asher JL, Ivey-Miranda J, Cox ZL, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Wilcox CS, Testani J. Renal negative pressure treatment as a novel therapy for heart failure-induced renal dysfunction. AJP Regulatory Integrative And Comparative Physiology 2021, 321: r588-r594. PMID: 34405731, DOI: 10.1152/ajpregu.00115.2021.Peer-Reviewed Original ResearchConceptsRenal plasma flowGlomerular filtration rateCongestive HFTubular pressureHeart failure hospitalizationPara-aminohippurate clearanceCentral venous pressureHigh fractional excretionNegative pressure therapyUrinary collecting systemNegative pressure treatmentSimilar diuresisFailure hospitalizationRenal dysfunctionCardiac tamponadeIothalamate clearanceFractional excretionRenal parametersKidney functionRenal congestionRenal responseRight kidneyVenous pressurePressure therapyControl kidneysMultinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience
Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, Tidwell W, Guide A, Testani JM, Lewis JB, Dwyer JP. Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. Journal Of Cardiac Failure 2021, 28: 21-31. PMID: 34403831, DOI: 10.1016/j.cardfail.2021.07.016.Peer-Reviewed Original ResearchConceptsAcute heart failureDiuretic resistanceDiuretic therapyHeart failureUrine outputSerum chemistryRenal replacement therapySingle medical centerSingle-center experienceAHF cohortDiuretic classesHospital mortalityTotal cohortKidney functionSerum sodiumCarbonic anhydrase inhibitorsProspective studyReplacement therapyCase-level evidenceRetrospective analysisMedical CenterDay 7Own controlTherapyPatientsConsensus conference on heart‐kidney transplantation
Kobashigawa J, Dadhania DM, Farr M, Tang WHW, Bhimaraj A, Czer L, Hall S, Haririan A, Formica RN, Patel J, Skorka R, Fedson S, Srinivas T, Testani J, Yabu JM, Cheng X, Participants T. Consensus conference on heart‐kidney transplantation. American Journal Of Transplantation 2021, 21: 2459-2467. PMID: 33527725, DOI: 10.1111/ajt.16512.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSimultaneous heart-kidney transplantHeart transplantKidney transplantationKidney diseaseConsensus conferenceEnd-stage heart diseaseConcomitant kidney diseaseDual-organ transplantationHeart-kidney transplantHeart-kidney transplantationMulti-organ transplantationReversible kidney injuryAdvanced kidney diseaseNon-inferior outcomesAvailable donor organsCardiorenal syndromeKidney injuryKidney functionStandardized careHeart diseaseSuccessful transplantationConsensus statementDonor organsOrgan transplantationTransplantation
2020
Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ. Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure. JACC Heart Failure 2020, 8: 537-547. PMID: 32535124, PMCID: PMC9027677, DOI: 10.1016/j.jchf.2020.03.009.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAcute decompensated heart failureDecompensated heart failureHeart failureKidney functionAdverse outcomesAcute declineNT-proBNPComposite outcomeNatriuretic peptideHigh riskMultivariable Cox regression modelsTotal proteinAcute kidney functionMarkers of decongestionN-terminal prohormoneGlomerular filtration rateCox regression modelEGFR declineCardiovascular deathVolume overloadFiltration rateEGFRHospital changesDecongestionEvaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology
Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal Of Heart Failure 2020, 22: 584-603. PMID: 31908120, DOI: 10.1002/ejhf.1697.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGlomerular filtration rateHeart failureKidney functionFiltration rateRenal functionSerum creatinineAcute heart failure episodeGuideline-directed medical therapyImproved long-term outcomesCardio-renal dysfunctionCardio-renal interactionsAcute heart failureChronic heart failureHeart Failure AssociationHeart failure careHeart failure stateHeart failure episodesAppropriate clinical contextLong-term outcomesRenal function assessmentFurther treatment strategiesNeurohumoral blockersLoop diureticsMedical therapyWorse outcomes
2019
Serum and Urine Albumin and Response to Loop Diuretics in Heart Failure
Charokopos A, Griffin M, Rao VS, Inker L, Sury K, Asher J, Turner J, Mahoney D, Cox ZL, Wilson FP, Testani JM. Serum and Urine Albumin and Response to Loop Diuretics in Heart Failure. Clinical Journal Of The American Society Of Nephrology 2019, 14: cjn.11600918. PMID: 31010938, PMCID: PMC6500945, DOI: 10.2215/cjn.11600918.Peer-Reviewed Original ResearchConceptsDiuretic efficiencyHeart failureAlbumin levelsDiuretic excretionDiuretic doseInpatient cohortUrine albuminOutpatient cohortLoop diureticsIL-6Higher urine albuminLoop diuretic doseUrinary albumin levelsLow serum albuminPlasma IL-6Heart failure cohortHuman heart failureDiuretic resistanceSuccessful decongestionDiuretic treatmentSystemic inflammationKidney functionSite of actionSerum albuminSodium output
2016
Renal dysfunction and chronic mechanical circulatory support
Brisco MA, Testani JM, Cook JL. Renal dysfunction and chronic mechanical circulatory support. Current Opinion In Cardiology 2016, 31: 277-286. PMID: 27022890, PMCID: PMC6176489, DOI: 10.1097/hco.0000000000000278.Peer-Reviewed Original ResearchConceptsMechanical circulatory supportRenal dysfunctionRenal functionCirculatory supportChronic mechanical circulatory supportPostoperative acute kidney injuryIrreversible renal dysfunctionAcute kidney injuryRight ventricular dysfunctionAdvanced heart failureCardiogenic shockKidney injuryNeurohormonal activationVentricular dysfunctionMost patientsHeart failureKidney functionSubsequent recurrenceVolume overloadVenous congestionEarly improvementDysfunctionDevice-related effectsReversible formDiagnostic tests
2015
Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials
Coca SG, Zabetian A, Ferket BS, Zhou J, Testani JM, Garg AX, Parikh CR. Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials. Journal Of The American Society Of Nephrology 2015, 27: 2529-2542. PMID: 26712525, PMCID: PMC4978048, DOI: 10.1681/asn.2015060642.Peer-Reviewed Original ResearchConceptsSerum creatinine levelsCreatinine levelsClinical trialsEnd pointAcute elevationRandomized trialsAcute changesPlacebo-controlled randomized trialSafety end pointRandomized clinical trialsStrong risk factorMeaningful clinical outcomesMeaningful end pointsClinical outcomesKidney functionPoor outcomeAcute increaseRisk factorsThorough literature searchObservational studyTemporary elevationMortality rateShort-term effectsPlaceboCKD
2013
Potential Effects of Digoxin on Long-Term Renal and Clinical Outcomes in Chronic Heart Failure
Testani JM, Brisco MA, Tang WH, Kimmel SE, Tiku-Owens A, Forfia PR, Coca SG. Potential Effects of Digoxin on Long-Term Renal and Clinical Outcomes in Chronic Heart Failure. Journal Of Cardiac Failure 2013, 19: 295-302. PMID: 23663810, PMCID: PMC3694335, DOI: 10.1016/j.cardfail.2013.03.002.Peer-Reviewed Original ResearchConceptsDigitalis Investigation GroupRenal dysfunctionHeart failureClinical outcomesFavorable renal responseHospitalization-free survivalLong-Term RenalChronic heart failureSerum creatinine levelsGlomerular filtration rateHypothesis-generating findingsLong-term improvementDIG trialCreatinine levelsRenal functionKidney functionRenal responseFiltration rateDigitalis glycosidesPatientsDigoxinHospitalizationDeathAdditional researchInvestigation group